Michael A. Bookman, MD

 

Professor of Medicine, The University of Arizona

 

E-Mail Address: 
Phone Number: 
(520) 626-3640
Fax: 
(520) 626-3663
Short Bio: 

Dr. Bookman is Professor of Medicine at The University of Arizona and in the Department of Medicine, providing leadership for clinical and research faculty within the Section, as well as The University of Arizona Cancer Center.

Dr. Bookman came to The University of Arizona Cancer Center in 2009 after serving 21 years at the Fox Chase Cancer Center in Philadelphia, PA, most recently as Vice President for Ambulatory Care and Clinical Research.  He is a renowned expert in gynecologic medical oncology with a focus on the development of new treatments for gynecologic cancers.  His interests include developmental therapeutics, medical information technology, collaborative research, and international outreach in gynecologic cancer management.

Butterfly_600.jpg

Dr. Bookman received his medical degree from Harvard Medical School, and he earned bachelor and master’s degrees from the Massachusetts Institute of Technology.

Other interests include astronomy, hiking, and photography.

 

 

Clinical Information
Specialty: 
Medical Oncologist
Clinical Focus: 

Clinical Practice Sites: 
The University of Arizona Cancer Center - Orange Grove
Research Information
Research Program: 
1. Therapeutic Development
Member Status: 
Member
Year of Membership Acceptance: 
2010
Selected Publications: 

Bookman MA, McMeekin DS, Fracasso P. Sequence-Dependence of Hematologic Toxicity Using Carboplatin and Topotecan for Primary Therapy of Advanced Epithelial Ovarian Cancer: A Phase I Study of the Gynecologic Oncology Group. Gynecol Oncol 103:473-8, 2006

Ozols RF, Bookman MA, Young RC. Intraperitoneal chemotherapy for ovarian cancer (letter). N Engl J Med. 354:1641-3, 2006

Parmar MK, Barthel FM, Sydes M, Langley R, Kaplan R, Eisenhauer E, Brady M, James N, Bookman MA, Swart AM, Qian W, Royston P. Speeding up the Evaluation of New Agents in Cancer. J Natl Cancer Inst 2008;100:1204-14. PMID: 18728279

Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, De Geest K, Mutch DG, Burger RA, Swart AM, Trimble EL, Accario-Winslow C, Roth LM. Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: a Phase III trial of the Gynecologic Cancer InterGroup (GCIG). J Clin Oncol 2009;27:1419-25. PMID: 19224846

Bookman MA. Trials with impact on clinical management: first line. Int J Gynecol Cancer. 2009(Suppl 2):S55-62. PMID: 19955916.

Bookman MA. Dose-dense chemotherapy in advanced ovarian cancer. Lancet 2009;374(9698):1303-5. PMID: 19767094

Rose PG, Tian C, Bookman MA. Assessment of tumor response as a surrogate endpoint of survival in recurrent platinum-resistant ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2010;117:324-9. PMID: 20185168.

Mackay HJ, Brady MF, Oza AM, Reuss A, Pujade-Lauraine E, Swart AM, Siddiqui N, Colombo N, Bookman MA, Pfisterer J, du Bois A; on behalf of the Gynecologic Cancer InterGroup. Prognostic Relevance of Uncommon Ovarian Histology in Women with Stage III/IV Epithelial Ovarian Cancer. Int J Gynecol Cancer 2010;20:945-952. PMID: 20683400.

Zaino RJ, Brady MF, Lele SM, Michael H, Greer B, Bookman MA. Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group Study. Cancer. 2010 Sep 22. [Epub ahead of print] PubMed PMID: 20862744.

Bookman MA: Update of randomized trials in first-line treatment. Ann Oncol. 22 Suppl 8:viii52-viii60, 2011. PMID: 22180402.

Bookman MA: First line therapy: have we made any improvement? Eur J Cancer. 47 Suppl 3:S93-103, 2011. PMID: 21944036.

Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX: Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 365:2473-2483, 2011. PMID: 22204724.

Zaino RJ, Brady MF, Lele SM, Michael H, Greer B, Bookman MA: Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group study. Cancer. 117:554-562, 2011. PMID: 20862744.

Rubatt JM, Darcy KM, Tian C, Muggia F, Dhir R, Armstrong DK, Bookman MA, Niedernhofer LJ, Deloia J, Birrer M, Krivak TC. 2012. Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: A gynecologic oncology group study. Gynecologic oncology. 16-Jan-2012 PMID: 22261301

Rungruang B, Miller A, Richard SD, Hamilton CA, Rodriguez N, Bookman MA, Maxwell GL, Krivak TC, Horowitz NS. 2012. Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease?: a Gynecologic Oncology Group study. Gynecologic oncology. 124:53-8 PMID: 22032836

Tian C, Ambrosone CB, Darcy KM, Krivak TC, Armstrong DK, Bookman MA, Davis W, Zhao H, Moysich K, Gallion H, Deloia JA. 2012. Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: A Gynecologic Oncology Group study. Gynecologic oncology. 124:575-81 PMID: 22112610 PMCID: PMC3278512

 

Collaborative Research: 

As Director of Educational Resources for the International Gynecologic Cancer Society (IGCS) since 2006, Dr. Bookman has collaborated on resources to support the educational mission of the Society, including international conferences and fellowships.LudhianaOR1.jpg

[IGCS-AGOI Surgical workshop, Ludhiana, Punjab, India with visiting surgeons Drs. Peter Heintz and Leon Massuger]

Within the Gynecologic Oncology Group (GOG), Dr. Bookman serves as Chair of the Ovarian Committee, as well as a member of the Protocol Development, Medical Oncology, Information Technology and Developmental Therapeutics Committees.  He is also the Principal Investigator for GOG0182-ICON5, an international phase III trial for patients with advanced ovarian cancer.

What prompted you to get into cancer research?: 

Professional Information
Board Certifications: 
Subspecialty Board, Medical Oncology (11/19/1985), American Board of Internal Medicine  (09/14/1983)
Professional Affiliations: 

American Association of Immunologists (AAI); American Association of Cancer Research (AACR); American Society of Clinical Oncology (ASCO); American Medical Informatics Association (AMIA); Clinical Immunology Society (CIS); International Gynecologic Cancer Society (IGCS); Pennsylvania Medical Society (PMS); Arizona Medical Association (ArMA)

Gynecologic Oncology Group (GOG);  SouthWest Oncology Group (SWOG);  NCI Gynecologic Cancer Steering Committee (GCSC) and Ovarian Task Force (OTF)

Senior Editor, International Journal of Gynecologic Cancer (LWW);  Editorial Board Member, Gynecologic Oncology (Academic Press);  Editorial Board Member, Journal of Clinical Oncology (WB Saunders)

Academic Information
Fellowship: 
Medicine Branch, National Cancer Institute, Bethesda, MD
Residency: 
Beth Israel Hospital, Boston, MA
Medical School: 
Harvard Medical School
Master's Degree: 
Massachusetts Institute of Technology
Undergraduate School: 
Massachusetts Institute of Technology